RxDoctor Payments Data

Patricia de Hof

Obstetrics & Gynecology · Silver Spring, MDNPI 1376611400

Payments from drug & device makers

$2,154in general payments, 2019–2025

Across 96 payments — averaging $22.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$582
  • Pfizer$381
  • Astellas Pharma US Inc$295
  • Sumitomo Pharma America, Inc.$195
  • Urovant Sciences Inc$183
  • Mayne Pharma Commercial LLC$66
  • plus $453 from 16 others

What the payments were for

  • Food & beverage$2,154100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,154 in reported general payments places this provider in the 75th percentile of 842 obstetrics & gynecology providers in Maryland.

See all obstetrics & gynecology providers in Maryland

Medicare billing

Part B allowed, 2024
$79,501
Medicare patients
362
Services billed
1,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron135$174,681
MyrbetriqMirabegron112$134,971
PremarinEstrogens, Conjugated104$48,425
Estradiol346$23,526
EstringEstradiol32$16,742
Methenamine Hippurate106$12,284
Estradiol (Once Weekly)Estradiol13$1,607
Estradiol (Twice Weekly)Estradiol13$1,471
Trimethoprim34$1,438
Clobetasol Propionate23$894
NitrofurantoinNitrofurantoin Macrocrystal17$886
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet24$852
ValacyclovirValacyclovir Hcl18$850
Fluconazole67$589
Cephalexin23$443

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$195$174,681135 claims
Astellas Pharma US IncMyrbetriq$295$134,971112 claims
PfizerPremarin, Estring$381$65,167136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 842 obstetrics & gynecology providers in Maryland.

Other obstetrics & gynecology in Silver Spring

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →